Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, and infertility.
The pairing of the capabilities of Evotec and Celmatix has the potential to impact the lives of millions of women living with these reproductive health conditions by bringing long overdue innovation in the form of therapies with novel mechanisms of action. In this research collaboration, Evotec will be responsible for medicinal chemistry, in vitro and in vivo pharmacology, in addition to its broad development capabilities and expertise, while Celmatix will contribute novel drug target discovery, powered by its proprietary multi-omics Reproductive Atlas™ platform.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are delighted to partner with Celmatix on this initiative. At Evotec we focus on patient-centric approaches and leveraging human genetic and big data into women’s health specific drug discovery is long overdue. We are convinced that our combined efforts will lead to highly innovative approaches with the potential to broadly impact women-focused unmet medical needs.”
“Reproductive health conditions collectively impact over 30% of women around the world and set the stage for later conditions such as cardiovascular disease and metabolic disorders. Endometriosis alone is estimated to cost the US economy over $78 billion annually, and available medical interventions have only limited utility. It’s time to move beyond the incremental improvements we have seen in the standard of care for these conditions and bring true innovation to the field.” said Dr Piraye Yurttas Beim, CEO and founder of Celmatix. “Through combining our vast datasets and deep expertise in women’s health with Evotec’s proven experience in therapeutic discovery, we are poised to catalyse real change and finally provide women therapies they deserve.”
No financial terms of this collaboration were disclosed.